Abstract: M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide is provided. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Abstract: The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences.

Abstract: M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Abstract: The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.

Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.

Abstract: Methods for preventing and treating osteolysis, cancer metastasis and bone loss associated with cancer metastasis by administering an M-CSF-antagonist in combination with a therapeutic agent to a subject are provided.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 9, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide is provided. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided.

Abstract: Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.